Radiotherapy and Immunotherapy Combinations in Non-small Cell Lung Cancer: A Promising Future?

Hanna, G.G.; Illidge, Tim

doi:10.1016/j.clon.2016.07.014

Cited by 9 publications

(8 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a small cohort of patients with skin and kidney cancer, stereotactic body radiotherapy with high dose IL2 showed better tumor response rates over that of IL2 alone [19]. There are several Phase I and 2 clinical trials ongoing in patients with NSCLC for evaluation of radiotherapy with PD-PDL1 immune checkpoint inhibitors, pembrolizumab, and nivolumab [20], outlined in Table 1.…”

Section: Combinatorial Approaches To Enhance Pd1-pdl1 Blockadementioning

confidence: 99%

Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System

Joshi

Durden

2019

Journal of Oncology

View full text Add to dashboard Cite

Cancer immunotherapy, including immune checkpoint blockade and adoptive CAR T-cell therapy, has clearly established itself as an important modality to treat melanoma and other malignancies. Despite the tremendous clinical success of immunotherapy over other cancer treatments, this approach has shown substantial benefit to only some of the patients while the rest of the patients have not responded due to immune evasion. In recent years, a combination of cancer immunotherapy together with existing anticancer treatments has gained significant attention and has been extensively investigated in preclinical or clinical studies. In this review, we discuss the therapeutic potential of novel regimens combining immune checkpoint inhibitors with therapeutic interventions that (1) increase tumor immunogenicity such as chemotherapy, radiotherapy, and epigenetic therapy; (2) reverse tumor immunosuppression such as TAMs, MDSCs, and Tregs targeted therapy; and (3) reduce tumor burden and increase the immune effector response with rationally designed dual or triple inhibitory chemotypes.

show abstract

Section: Combinatorial Approaches To Enhance Pd1-pdl1 Blockadementioning

confidence: 99%

Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System

Joshi

Durden

2019

Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…интерферона I типа, увеличение главного комплекса гистосовместимости, экспрессию неоантигенов и индукцию иммуногенной смерти клеток [24][25][26][27]. Другие элементы иммунной модуляции включают изменения в механизме представления антигена и транслокации кальретикулина на поверхности клетки [28].…”

Section: Reviews Of Literatureunclassified

The combination of immunotherapy and radiation therapy for non-small cell lung cancer

Ragulin¹

2018

Onkol. Z. im. P.A. Gercena

View full text Add to dashboard Cite

Медицинский радиологический научный центр им. А.Ф. Цыба-филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава России, Москва, Россия В обзоре приведены данные литературы по лечению немелкоклеточного рака легкого с использованием сочетания иммунотерапии и лучевой терапии. Рассмотрены возможные механизмы усиления противоопухолевого воздействия, реализуемого сочетанием лучевой и иммунотерапии, а также результаты клинических исследований, посвященных этому вопросу. Ключевые слова: немелкоклеточный рак легкого, лучевая терапия, иммунотерапия, комбинированное лечение.

show abstract

“…Recent preclinical and clinical studies have led to interest in the potential of RT to improve the efficacy of concurrent or subsequent immunotherapy . A phase III study demonstrated that durvalumab, a PD‐1 ligand inhibitor, administered after a combination of RT and chemotherapy for locally advanced lung cancer led to a significantly longer progression‐free survival (PFS) .…”

Section: Introductionmentioning

confidence: 99%

Prior or concurrent radiotherapy and nivolumab immunotherapy in non–small cell lung cancer

Ratnayake

Shanker

Roberts

et al. 2019

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

Background: Studies suggest that combining radiotherapy (RT) with programmed cell death protein 1 (PD-1) blockade may elicit a synergistic antitumor response. We aimed to assess whether prior or concurrent RT was associated with improved disease control in patients with metastatic non-small cell lung cancer (NSCLC) treated with nivolumab. Methods:We conducted a retrospective study of patients receiving nivolumab as second or subsequent line therapy for metastatic NSCLC. Patients were categorized into those who received any RT for NSCLC prior to or during nivolumab therapy, and those with no history of RT for NSCLC.Results: A total of 85 patients received nivolumab between July 2015 and December 2016 and were followed up for a median of 15 months. Sixty-five patients (76.4%) received RT prior to or during nivolumab and 20 patients (23.6%) received nivolumab alone. Baseline characteristics of age, performance status, histology, smoking status and previous therapy were similar between the two groups. Prior or concurrent RT was associated with a superior PFS, median 2.8 months with RT versus 1.3 months without RT (Hazard Ratio (HR) = 0.494; 95% Confidence Interval (CI), 0.279-0.873; P = 0.02). The median OS of the group receiving RT was 6.4 months versus 4.2 months for the no RT group (P = 0.20). RT was not associated with an increase in toxicity. Conclusion:RT prior to or concurrent with nivolumab for metastatic NSCLC was associated with a modest improvement in PFS over nivolumab alone with no evidence of increase in adverse effects.RT may potentiate the effect of anti-PD-1 immunotherapy in NSCLC. K E Y W O R D Simmunotherapy, non-small cell lung cancer, radiotherapy

show abstract

Radiotherapy and Immunotherapy Combinations in Non-small Cell Lung Cancer: A Promising Future?

Cited by 9 publications

References 40 publications

Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System

Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System

The combination of immunotherapy and radiation therapy for non-small cell lung cancer

Prior or concurrent radiotherapy and nivolumab immunotherapy in non–small cell lung cancer

Contact Info

Product

Resources

About